WASHINGTON, Jan 11 (Reuters) - The U.S. Food and Drug Administration is focused on reviewing at-home and other COVID-19 tests, particularly those that can be manufactured at scale, Acting FDA Commissioner Janet Woodcock said at a Senate hearing on Tuesday. (Reporting by Susan Heavey)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.145 USD | +0.08% | -2.92% | -24.94% |
Feb. 27 | Transcript : OraSure Technologies, Inc., 2023 Earnings Call, Feb 27, 2024 | |
Feb. 27 | Earnings Flash (OSUR) ORASURE TECHNOLOGIES Posts Q4 Revenue $75.9M, vs. Street Est of $74.3M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.94% | 453M | |
+3.01% | 197B | |
+5.92% | 115B | |
+1.48% | 71.22B | |
+12.49% | 53.77B | |
+17.63% | 48.75B | |
+6.87% | 44.22B | |
+12.46% | 28.85B | |
+10.08% | 28.57B | |
+10.35% | 27.62B |
- Stock
- Equities
- Stock OraSure Technologies, Inc. - Nasdaq
- News OraSure Technologies, Inc.
- Review of COVID-19 tests remains top priority -acting U.S. FDA chief